NCT01158417.
Trial name or title | Acronym: — |
Methods |
Type of trial: efficacy trial Allocation: randomised Intervention model: parallel assignment Masking: single‐blind (participant) Primary purpose: treatment |
Participants |
Condition: type 2 diabetes mellitus, obesity, and Insulin resistance Enrolment: estimated 102 Inclusion criteria
Exclusion criteria
|
Interventions |
Intervention(s): resveratrol (40 mg oral 3 times a day or 500 mg oral once daily) Comparator(s): placebo tablets |
Outcomes |
Primary outcome(s): NF‐Kb Secondary outcome(s): GLP‐1 Other outcome(s): — |
Starting date |
Trial start date: December 2008 Trial completion date: August 2014 (estimated) |
Contact information | Responsible party/principal investigator: Paresh Dandona, MD, Kaleida Health |
Study identifier | Trial identifier:NCT01158417 |
Official title | Effect of resveratrol on insulin resistance and inflammatory mediators in obese and type 2 diabetic subjects |
Stated purpose of study | Quote: "The main objective of this study is to investigate the effect of resveratrol on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2 diabetic subjects in vivo" |
Notes |